The FY2025 (Dec) proxy of Protagonist Therapeutics names 19 peer companies for pay. Among Protagonist Therapeutics and these peers, CEO pay was 2nd highest of 5 and total shareholder return was 2nd highest of 5.
2nd highest of 5in Protagonist Therapeutics and its pay peers, FY2025 (Dec) by CEO pay:
$5.4M$21.3M
2nd highest of 5in Protagonist Therapeutics and its pay peers, FY2025 (Dec) by total shareholder return:
$63$625
Pay peer group, FY2025 (Dec) proxy
| Viking Therapeutics | ||
| Cytokinetics | ||
| IDEAYA Biosciences | ||
| Agios Pharmaceuticals | ||
| Akero Therapeutics, Inc. | Not disclosed | Not disclosed |
| Arcellx, Inc. | Not disclosed | Not disclosed |
| Biohaven, Ltd. | Not disclosed | Not disclosed |
| Celldex Therapeutics, Inc. | Not disclosed | Not disclosed |
| Crinetics Pharmaceuticals, Inc. | Not disclosed | Not disclosed |
| Denali Therapeutics, Inc. | Not disclosed | Not disclosed |
| Disc Medicine, Inc. | Not disclosed | Not disclosed |
| Geron Corporation | Not disclosed | Not disclosed |
| Immunovant, Inc. | Not disclosed | Not disclosed |
| Keros Therapeutics, Inc. | Not disclosed | Not disclosed |
| Kura Oncology, Inc. | Not disclosed | Not disclosed |
| Nurix Therapeutics, Inc. | Not disclosed | Not disclosed |
| Rhythm Pharmaceuticals | Not disclosed | Not disclosed |
| Structure Therapeutics, Inc. | Not disclosed | Not disclosed |
| Syndax Pharmaceuticals, Inc. | Not disclosed | Not disclosed |
19 companies
Changes by year
No proxy on file names a change to the peer group.
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year. Each company counts TSR from its own start year, so two values compare only when the start years match.